文献速递心脑血管急症

DEBUT试验:高出血风险患者新发冠状动脉病变的药物涂层球囊治疗——单盲、随机、非劣效性试验

Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
PubMed 文献 · Lancet · 2019-06-13
一句话结论高出血风险患者新发冠脉病变,药物涂层球囊9个月主要不良心脏事件劣于或优于裸金属支架:1% vs 14%,绝对风险差-13.2个百分点,支持药物涂层球囊优于裸金属支架。

DEBUT试验在芬兰5个中心纳入220例高出血风险、新发冠脉或桥血管病变且参考血管直径2.5-4.0 mm的患者,预扩张成功后随机接受紫杉醇碘普罗胺涂层球囊(n=102)或裸金属支架(n=106)。9个月主要不良心脏事件药物涂层球囊组1% vs 裸金属支架组14%,绝对风险差-13.2个百分点(95%CI -6.2至-21.1),风险比0.07(95%CI 0.01至0.52),非劣效性和优效性均达统计学显著。裸金属支架组发生2例确定性支架血栓,药物涂层球囊组无急性血管闭塞。作者认为药物涂层球囊优于裸金属支架,未来需与新一代药物洗脱支架比较。

要点

  • 高出血风险新发冠脉病变预扩张成功后,药物涂层球囊9个月主要不良心脏事件1% vs 裸金属支架14%,绝对风险差-13.2个百分点(95%CI -6.2至-21.1)。
  • 药物涂层球囊组风险比为0.07(95%CI 0.01至0.52),非劣效性p<0.00001,优效性p=0.00034。
  • 裸金属支架组发生2例确定性支架血栓,药物涂层球囊组无急性血管闭塞。
  • 适用条件:参考血管直径2.5-4.0 mm、至少一项出血危险因素、预扩张成功后无血流限制性夹层或明显回缩(>30%)。
  • 排除ST段抬高型心肌梗死、需双支架技术的分叉病变、支架内再狭窄。

适用人群与场景

  • 高出血风险患者,冠脉或桥血管新发缺血性病变,可用药物涂层球囊治疗,参考血管直径2.5-4.0 mm,至少一项出血危险因素。
  • 排除ST段抬高型心肌梗死、需双支架技术的分叉病变、支架内再狭窄、预扩张后血流限制性夹层或目标病变明显回缩(>30%)者。

处置流程与药物剂量

  • 目标病变预扩张成功后,随机接受紫杉醇和碘普罗胺涂层球囊经皮冠状动脉介入治疗或裸金属支架置入。

红旗征与不能漏的情况

  • 预扩张后出现血流限制性夹层或目标病变明显回缩(>30%)者被排除,不进入随机分组。

研究设计与关键结果

  • 随机、单盲、非劣效性试验,芬兰5个中心,2013年5月22日至2017年1月16日招募220例,208例随机分配至药物涂层球囊组(n=102)或裸金属支架组(n=106)。
  • 9个月主要不良心脏事件:药物涂层球囊组1例(1%)vs 裸金属支架组15例(14%),绝对风险差-13.2个百分点(95%CI -6.2至-21.1),风险比0.07(95%CI 0.01至0.52),非劣效性p<0.00001,优效性p=0.00034。
  • 裸金属支架组发生2例确定性支架血栓,药物涂层球囊组无急性血管闭塞。

证据类型、等级与局限

  • 随机、单盲、非劣效性试验,非劣效界值为绝对风险差不超过3%,所有预设分析在意向治疗人群中进行。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在高出血风险患者中,药物涂层球囊经皮冠状动脉介入治疗优于裸金属支架。
  • 作者认为,药物涂层球囊-only冠脉介入是治疗这一困难患者群体的新策略。
  • 作者认为,未来需将该方法与新一代药物洗脱支架进行比较。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal technique of percutaneous coronary intervention in patients at high bleeding risk is not known. The hypothesis of the DEBUT trial was that percutaneous coronary intervention with drug-coated balloons is non-inferior to percutaneous coronary intervention with bare-metal stents for this population.

METHODS: The DEBUT trial is a randomised, single-blind non-inferiority trial done at five sites in Finland. Patients were eligible if they had an ischaemic de-novo lesion in a coronary artery or bypass graft that could be treated with drug-coated balloons, at least one risk factor for bleeding, and a reference vessel diameter of 2·5-4·0 mm. Those with myocardial infarction with ST-elevation, bifurcation lesions needing a two-stent technique, in-stent restenosis, and flow-limiting dissection or substantial recoil (>30%) of the target lesion after predilation were excluded. After successful predilation of the target lesion, patients were randomly assigned (1:1), by use of a computer-generated random sequence, to percutaneous coronary intervention with a balloon coated with paclitaxel and iopromide or a bare-metal stent. The primary outcome was major adverse cardiac events at 9 months. Non-inferiority was shown if the absolute risk difference was no more than 3%. All prespecified analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01781546.

FINDINGS: Between May 22, 2013, and Jan 16, 2017, 220 patients were recruited for the study and 208 patients were assigned to percutaneous coronary intervention with drug-coated balloon (n=102) or bare metal stent (n=106). At 9 months, major adverse cardiac events had occurred in one patient (1%) in the drug-coated balloon group and in 15 patients (14%) in the bare-metal stent group (absolute risk difference -13·2 percentage points [95% CI -6·2 to -21·1], risk ratio 0·07 [95% CI 0·01 to 0·52]; p<0·00001 for non-inferiority and p=0·00034 for superiority). Two definitive stent thrombosis events occurred in the bare metal stent group but no acute vessel closures in the drug-coated balloon group.

INTERPRETATIONS: Percutaneous coronary intervention with drug-coated balloon was superior to bare-metal stents in patients at bleeding risk. The drug-coated balloon-only coronary intervention is a novel strategy to treat this difficult patient population. Comparison of this approach to the new generation drug-eluting stents is warranted in the future.

FUNDING: B Braun Medical AG, AstraZeneca, and Competitive State Research Funding of the Kuopio University Hospital Catchment Area.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019. PMID: 31204115. doi:10.1016/S0140-6736(19)31126-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。